HLB Pharmaceutical Co. Ltd (047920) — Cash Flow Quality Index
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow Quality Index of -0.68x as of March 2025. Operating cash flow of ₩-1.07 Billion is below net income of ₩1.57 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore cash efficiency ratio of HLB Pharmaceutical Co. Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
HLB Pharmaceutical Co. Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for HLB Pharmaceutical Co. Ltd across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check HLB Pharmaceutical Co. Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year earnings quality comparison for HLB Pharmaceutical Co. Ltd. For live market cap and the full company financial profile, see HLB Pharmaceutical Co. Ltd market cap and net worth.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 3.39x | ₩6.84 Billion | ₩2.02 Billion | ▲ +18.3% |
| 2019 | 2.86x | ₩1.35 Billion | ₩472.66 Million | ▲ +875.8% |
| 2016 | -0.37x | ₩-213.11 Million | ₩577.41 Million | ▼ -107.3% |
| 2014 | 5.06x | ₩1.54 Billion | ₩304.58 Million | — |